EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Soluble Epoxide Hydrolase Inhibitor: Toward Regulatory Preclinical Studies

Júlia Jarne-Ferrer, Javier Sánchez, Sandra Codony, Marion Schneider, Christa E Müller iD, Coral Sanfeliu, Rafael Franco iD, Santiago Vazquez iD, Christian Griñán-Ferré iD, Mercè Pallàs iD

ACS Pharmacology & Translational Science · 14.02.2025 · 8 (2) · 533-542

DOI: 10.1021/acsptsci.4c00629 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 29.01.2025. Verfasst von Júlia Jarne-Ferrer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Departament de Farmacologia i Química Terapèutica, Institut de Neurociències-Universitat de Barcelona, 08028 Barcelona, Spain. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovaci?n y Universidades, Agencia Estatal de Investigaci?n, Ministerio de Econom?a y Competitividad.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroinflammation is widely recognized as a key pathological hallmark of Alzheimer's disease (AD). Recently, inhibiting soluble epoxide hydrolase (sEH) has emerged as a promising therapeutic strategy for AD. sEH plays a pivotal role in neuroinflammation by hydrolyzing epoxyeicosatrienoic acids (EETs), which have anti-inflammatory and neuroprotective properties, into pro-inflammatory dihydroepoxyeicosatrienoic acids (DHETs). Furthermore, the overexpression of the enzyme in the brains of AD patients and animal models of the disease highlights its relevance as a therapeutic target. Our previous studies, using the inhibitor UB-SCG-51 demonstrated that sEH inhibition regulates neuroinflammation and other mechanisms, such as the unfolded protein response pathway, while reducing autophagy, apoptosis, and neuronal death, thereby promoting neuroprotection. Building on these findings, we evaluated the arginine salt of the compound, designated UB-SCG-74, which offers improved oral absorption compared to that of UB-SCG-51 while retaining high permeability, potency, and selectivity. In experiments using 5XFAD mice, UB-SCG-74 treatment significantly improved cognition and synaptic plasticity, outperforming donepezil, a standard AD drug, and ibuprofen, an anti-inflammatory drug. Remarkably, these benefits persisted for 4 weeks after administration cessation, suggesting lasting therapeutic effects. Safety pharmacology studies showed no toxicity, supporting the advancement of UB-SCG-74 into preclinical regulatory evaluation. Our findings further indicate that sEH inhibition engages multiple neuroprotective pathways, potentially modifying both AD symptoms and disease progression, thus reinforcing its therapeutic potential.

Autor:innen und Institutionen

  • Departament de Farmacologia i Química Terapèutica, Institut de Neurociències-Universitat de Barcelona, 08028 Barcelona, Spain.
  • Laboratori de Química Farmacèutica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, 08028 Barcelona, Spain.
  • Institute of Biomedicine of the University of Barcelona (IBUB), Universitat de Barcelona, 08028 Barcelona, Spain.
  • PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, 53121 Bonn, Germany.
  • Institute of Biomedical Research of Barcelona (IIBB), CSIC, 08036 Barcelona, Spain.
  • Centro de Investigación en Red, Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28029 Madrid, Spain.

ORCID-Profile: Christa E Müller, Rafael Franco, Santiago Vazquez, Christian Griñán-Ferré, Mercè Pallàs

Förderung

  • Ministerio de Ciencia, Innovaci?n y Universidades
  • Agencia Estatal de Investigaci?n
  • Ministerio de Econom?a y Competitividad
  • Ag?ncia de Gesti? d'Ajuts Universitaris i de Recerca
  • NextGenerationEU

Zitieren

APA

Jarne-Ferrer, J., Sánchez, J., Codony, S., Schneider, M., Müller, C. E., Sanfeliu, C., Franco, R., Vazquez, S., Griñán-Ferré, C., & Pallàs, M. (2025). Novel Soluble Epoxide Hydrolase Inhibitor: Toward Regulatory Preclinical Studies. ACS Pharmacology & Translational Science, 8(2), 533-542. https://doi.org/10.1021/acsptsci.4c00629

Vancouver

Jarne-Ferrer J, Sánchez J, Codony S, Schneider M, Müller CE, Sanfeliu C, et al. Novel Soluble Epoxide Hydrolase Inhibitor: Toward Regulatory Preclinical Studies. ACS Pharmacology & Translational Science. 2025;8(2):533-542. doi:10.1021/acsptsci.4c00629

BibTeX
@article{JarneFerrer2025,
  author = {Jarne-Ferrer, Júlia and Sánchez, Javier and Codony, Sandra and Schneider, Marion and Müller, Christa E and Sanfeliu, Coral and Franco, Rafael and Vazquez, Santiago and Griñán-Ferré, Christian and Pallàs, Mercè},
  title = {Novel Soluble Epoxide Hydrolase Inhibitor: Toward Regulatory Preclinical Studies},
  journal = {ACS Pharmacology & Translational Science},
  year = {2025},
  volume = {8},
  number = {2},
  pages = {533--542},
  doi = {10.1021/acsptsci.4c00629}
}
Kostenlos starten →